Changes in Beneficial Ownership · 4
STAAR Surgical Company
STAANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- STAAR SURGICAL CO
- Issuer CIK
- 0000718937
- Trading symbol
- STAA
Reporting owner 1
- Name
- Michna Magda
- Reporting owner CIK
- 0001731487
- Relationship
- Officer
- Officer title
- Chief Development Officer
- Address
- 25510 COMMERCENTRE DRIVE, LAKE FOREST, CA, 92630
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-14 | M · Form 4 | 5,499 | A | 0 | 43,599[F1] | D |
| Common Stock | 2026-08-14 | F · Form 4 | 2,797[F2] | D | 26.18 | 40,802 | D |
| Common Stock | 2026-08-14 | F · Form 4 | 559 | D | 26.18 | 40,243 | D |
| Common Stock | 2026-08-14 | M · Form 4 | 1,100 | A | 26.18 | 41,343 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Units | 0 | 2026-08-14 | M · Form 4 | 5,499 | A | 0 | [F3] | 2027-12-31 | Common Stock | 5,499 | 5,499 | D |
| Performance Stock Units | 0 | 2026-08-14 | M · Form 4 | 1,100 | A | 0 | [F4] | 2027-12-31 | Common Stock | 1,100 | 1,100 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Due to clerical errors, the Reporting Person's prior Form-4 filed with the Securities and Exchange Commission on May 12, 2026 incorrectly reported this value as 32,691 shares when the Reporting Person beneficially owned 28,008 shares and the Reporting Person's prior Form 4 filed with the SEC on May 19, 2026 incorrectly reported this value as 46,026 when the Reporting Person beneficially owned 38.100. The values have been corrected herein.↩ 1
- F2
- On August 14, 2026, the third tranche of 5,499 performance stock units ("PSUs") awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program ("2025 PSU Program") in connection with her annual equity grant vested, of which 2,797 shares were withheld to satisfy taxes.↩ 1
- F3
- Represents the settlement of the third tranche of 5,499 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her annual equity grant vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1
- F4
- Represents the settlement of the third tranche of of 1,100 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her promotion to Chief Development Officer vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1
Signature 1
- Signed
- /s/ Magda Michna
- Date
- 2026-08-18
Company context
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding STAAR SURGICAL CONov 16, 2026
- 10-Q filingNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 10, 2026